Studies related to Glucagon-like peptide 1 (GLP-1) and Cannabis

Effects Of Oral, Smoked, And Vaporized Cannabis On Endocrine Pathways Related To Appetite And Metabolism: A Randomized, Double-Blind, Placebo-Controlled, Human Laboratory Study

Effect Decrease
Values Oral cannabis caused a significant reduction in GLP-1 100 minutes after administration, but smoked and vaporized cannabis did not have the same effect.
Trial Design Randomized trial
Trial Length 24 hours
Number of Subjects 20
Sex n/a
Age Range 18-29, 30-44
Notes for this study:
In this crossover study, participants completed four three-hour treatments in random order, separated by at least 72 hours: oral placebo plus smoked/vaporized placebo, oral cannabis (in the form of a fudge brownie) plus smoked/vaporized placebo, oral placebo plus smoked cannabis, and oral placebo plus vaporized cannabis. The oral treatment was given first, and the smoked/vaporized treatment was given 10 minutes later. In each treatment, the participants received about 50 mg THC.

Blood was drawn twice prior to receiving the treatment, and 5, 15, and 1 hour and 20 minutes after smoked or vaporized cannabis was administered, or 25, 40, and 1 hour and 40 minutes after oral cannabis was administered.